Picture of Alligator Bioscience AB logo

ATORX Alligator Bioscience AB News Story

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Brief: Alligator Bioscience Announces Positive Mitazalimab Optimize-1 Phase 2 Results

Jan 29 (Reuters) - Alligator Bioscience AB  ATORX.ST :
    * ANNOUNCES POSITIVE MITAZALIMAB OPTIMIZE-1 PHASE 2 RESULTS
MEETING PRIMARY ENDPOINT AND DEMONSTRATING CLINICALLY RELEVANT
SURVIVAL BENEFITS IN 1ST LINE PANCREATIC CANCER
    * DISCUSSIONS WITH FDA CONFIRM A CLEAR APPROVAL PATHWAY WITH
PHASE
3 REGISTRATION STUDY ON TRACK TO START IN EARLY 2025

Source text for Eikon:  ID:nMFN3c3NSL 
Further company coverage:  ATORX.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))

Recent news on Alligator Bioscience AB

See all news